Abstract | OBJECTIVE: DATA SOURCES: A literature search using MEDLINE (1966-July 2014) and EMBASE (1973-July 2014) was conducted using the search terms memantine, headache, migraine, glutamate, and NMDA. References of identified articles were reviewed for additional, relevant citations. STUDY SELECTION AND DATA EXTRACTION: DATA SYNTHESIS: Data from several retrospective reports and 2 prospective clinical trials suggest that memantine may be a useful treatment option for the prevention of primary headache disorders. The majority of available literature focuses specifically on chronic migraine prevention in refractory patients who had failed multiple previous prophylactic therapies. In these patients, 10 to 20 mg of memantine daily reduced the frequency and intensity of migraine headaches and was generally well tolerated, with few adverse events. Data regarding the efficacy of memantine for other primary headache disorders such as chronic tension type and cluster headaches are limited. CONCLUSION:
|
Authors | Linda Huang, Michael Bocek, Joseph K Jordan, Amy Heck Sheehan |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 48
Issue 11
Pg. 1507-11
(Nov 2014)
ISSN: 1542-6270 [Electronic] United States |
PMID | 25159002
(Publication Type: Journal Article, Review)
|
Copyright | © The Author(s) 2014. |
Chemical References |
|
Topics |
- Analgesics
(therapeutic use)
- Clinical Trials as Topic
- Headache Disorders, Primary
(drug therapy)
- Humans
- Memantine
(therapeutic use)
- Migraine Disorders
(drug therapy)
|